4 Jun 2021 8:54 am
Oh, so now your trying to change the narrative to Trump , you disingenuous prick. Your obsessed with Trump being wrong.Vegasgiants » 04 Jun 2021, 8:10 am » wrote: ↑ Yeah trump was **** wrong. It DID NOT HELP PREVENT COVID IN HIM.
HE GOT COVID ANYWAY AND WHEN HE DID HE SURE DID NOT TAKE IVERMECTIN
NOW DENY THAT IDIOT. LOL
You put your faith (because you are a ****, moonbatty sheople) in what your are told by big pharma and the lapdog, enemy of the people, lying, leftist, in this case big pharma controlled media. Their claim that Ivermectin has not been tested and therefore unproven is a lie.
Remdesivir: Remdesivir is an anti-viral drug that is given intravenously. Two randomized controlled trials found that the drug improved the outcomes for patients hospitalized for COVID-19. In October, the Food and Drug Administration approved remdesivir as a treatment for COVID-19.
(2-TWO randomized trials and the big pharma owned FDA approves its use, ****!!!)
Baricitinib: A drug originally marketed to treat rheumatoid arthritis, in November, the FDA issued an emergency use authorization for baricitinib as a treatment for COVID-19. An emergency use authorization allows the FDA to approve the use of a treatment during an emergency without the same level of evidence that would fully establish its effectiveness and safety. (Again the FDA approved its use without the standard level of testing)Bamlanivimab: Bamlanivimab is a monoclonal antibody produced by Eli Lilly to treat COVID-19. Monoclonal antibodies are proteins developed in a laboratory that are designed to mimic the way the immune system attacks a pathogen. One randomized controlled trial has found that bamlanivimab reduced the amount of the coronavirus and symptoms in outpatients. It also slightly reduced the number of patients who had to be hospitalized or go to the emergency room. Yet this was only phase two of the trial. A larger phase three needs to be conducted before the full safety and efficacy of the treatment can be determined.
That was enough for the FDA to issue an emergency use authorization for bamlanivimab as a treatment for COVID-19 in November. In response to the FDA’s action, the National Institutes of Health later released a statement saying at present, "there are insufficient data to recommend either for or against the use of bamlanivimab for the treatment of outpatients with mild to moderate COVID-19. ( Approved by the FDA with insufficient testing!!!)
REGN-COV2: This treatment is a cocktail of two monoclonal antibodies, casirivimab and imdevimab, produced by Regeneron. In September, Regeneron released preliminary findings of 275 patients and found that the treatment had reduced the amount of the coronavirus in outpatients. Regeneron released more data in October of 524 patients that showed that the amount of the coronavirus in outpatients who received REGN-COV2 dropped by tenfold when compared to patients who received a placebo. A larger trial of REGN-COV2 is ongoing.
In November, the FDA issued an emergency use authorization for REGN-COV2 as a treatment for COVID-19 in outpatients. However, the NIH released a statement saying there was not yet sufficient data to recommend REGN-COV2 as a treatment for COVID-19. (Enough said)
Convalescent plasma: This is plasma from people who have recovered from COVID-19 and then infused into a patient who is suffering from the virus. In theory, convalescent plasma contains antibodies that can fight the infection. In August, the FDA issued an emergency use authorization for convalescent plasma. However, the evidence supporting convalescent plasma is weak, leading the NIH to disagree with the FDA’s decision.
A Mayo Clinic study of 35,000 patients found a lower death rate among COVID-19 patients given convalescent plasma within three days of diagnosis versus those who were given it after four days or more. Yet the study lacked a control group, so it is unclear if the lower death rate was caused by the treatment or other factors.
A Chinese study found positive results for convalescent plasma but only had 10 patients in the study. A larger Chinese study of 103 patients found no positive impact. (Again an approval from the FDA with insufficient evidence of it effectiveness)
Corticosteroids: These types of steroids have been used for years to treat autoimmune diseases. A trial in the United Kingdom found COVID-19 patients treated with one type of corticosteroid, dexamethasone, had a slightly lower death rate than patients who were not treated with it. It seemed to work particularly well for patients who needed a ventilator.
Additionally, a meta-analysis of seven randomized trials found that patients hospitalized with COVID-19 who took a corticosteroid had a lower death rate than those who did not. At present, though, neither the FDA nor the WHO recommends corticosteroids as a treatment for COVID-19. (Hmm, found to work but not recommended by the big pharma owned FDA)
Hydroxychloroquine: This is another drug that was given an emergency use authorization by the FDA to treat COVID-19. When the FDA gave the authorization in March, it based it on limited research done in a laboratory and anecdotal clinical data. In July, the FDA revoked hydroxychloroquine’s emergency use authorization as more data showed that it was not effective at treating COVID-19. Big pharma owned FDA approved based on LIMITED RESEARCH!!!)
Ivermectin: Ivermectin is an anti-parasite drug that has shown promise in the laboratory as a treatment that can reduce the amount of the coronavirus. But research in the laboratory conducted on cell cultures is quite different than actually testing it on human beings. A journal article reviewing the laboratory research concluded that the doses of ivermectin used in the laboratories were too large to be used safely in humans.
\
But a group of physicians calling themselves the Front Line Covid-19 Critical Care Alliance has released a review of the research on invermectin as a treatment in actual COVID-19 patients. Much of the research involves using safe dosages in randomized controlled trials. The overall results are promising, showing that those who took invermectin had a shorter duration of symptoms. But critics have attacked those studies for having small sample sizes that can lead to biased outcomes. ( Completely ignoring the fact that Ivvermectin has been given to 100's of 100,00's around the world showing its effectiveness against the kung flu with virtually no adverse side effects)
https://www.msn.com/en-us/health/medica ... r-BB1cpYTH
Why is the effectiveness of Ivermectin being ignored? BECAUSE BIG PHARMA CANNOT PROFIT $BILLIONS FROM IVERMECTIN BECAUSE THEY CANNOT RENAME IT AND PATENT IT AND JACK UP THE PRICE.
**** you you disingenuous, ****, moonbatty, lying idiot!!!